65 related articles for article (PubMed ID: 7764055)
1. Genotoxic risk of quinocetone and its possible mechanism in
Wang X; Yang P; Li J; Ihsan A; Liu Q; Cheng G; Tao Y; Liu Z; Yuan Z
Toxicol Res (Camb); 2016 Mar; 5(2):446-460. PubMed ID: 30090359
[TBL] [Abstract][Full Text] [Related]
2. Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells.
Choi CY; Lim SC; Lee TB; Han SI
Nutrients; 2022 Feb; 14(3):. PubMed ID: 35277058
[TBL] [Abstract][Full Text] [Related]
3. Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors.
Ma Y; Wang JG; Wang B; Li ZM
J Mol Model; 2011 Aug; 17(8):1899-909. PubMed ID: 21107989
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.
Zheng X; Chu F; Chou PM; Gallati C; Dier U; Mirkin BL; Mousa SA; Rebbaa A
Am J Physiol Cell Physiol; 2009 Jan; 296(1):C65-74. PubMed ID: 18971393
[TBL] [Abstract][Full Text] [Related]
5. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
Bidwell GL; Davis AN; Fokt I; Priebe W; Raucher D
Invest New Drugs; 2007 Aug; 25(4):313-26. PubMed ID: 17483874
[TBL] [Abstract][Full Text] [Related]
6. An etoposide-induced block in vaccinia virus telomere resolution is dependent on the virus-encoded DNA ligase.
DeLange AM; Carpenter MS; Choy J; Newsway VE
J Virol; 1995 Apr; 69(4):2082-91. PubMed ID: 7884854
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase I and II as targets for rational design of new anticancer drugs.
Cummings J; Smyth JF
Ann Oncol; 1993 Aug; 4(7):533-43. PubMed ID: 8395870
[TBL] [Abstract][Full Text] [Related]
8. Clinical resistance to topoisomerase-targeted drugs.
Dingemans AM; Pinedo HM; Giaccone G
Biochim Biophys Acta; 1998 Oct; 1400(1-3):275-88. PubMed ID: 9748627
[TBL] [Abstract][Full Text] [Related]
9. Altered DNA topoisomerase II in multidrug resistance.
Beck WT; Danks MK; Wolverton JS; Granzen B; Chen M; Schmidt CA; Bugg BY; Friche E; Suttle DP
Cytotechnology; 1993; 11(2):115-9. PubMed ID: 7764055
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
11. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
13. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
[TBL] [Abstract][Full Text] [Related]
14. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
15. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]